ARIX BIOSCIENCE PLC

Net Asset Value • Jan 19, 2024

National Storage Mechanism | Additional information

Arix Bioscience PLC (ARIX)

Unaudited NAV for December 2023

19-Jan-2024 / 07:00 GMT/BST

---

Arix Bioscience plc

Unaudited NAV for December 2023

LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 31 December 2023 as follows:

Date	NAV Breakdown				Total NAV	NAV per share
Listed Portfolio	Unlisted Portfolio	Cash	Other Interests
31 December 2023 (unaudited)	£59.2m	£66.2m	£106.2m	£2.6m	£234.2m	£1.81

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Powerscourt Group

Sarah MacLeod, Nick Johnson, Molly Ring

+44 (0)20 7250 1446

arix@powerscourt-group.com

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

---

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.

---

ISIN:	GB00BD045071
Category Code:	MSCM
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	298384
EQS News ID:	1818407

End of Announcement	EQS News Service

---